Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
Open accessThe DOI matches its Crossref record; 75 of the 79 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cyclin-dependent kinases (CDKs) regulate cell proliferation and coordinate the cell cycle checkpoint response to DNA damage. Although inhibitors with varying selectivity to specific CDK family members have been developed, selective CDK4/6 inhibitors have emerged as the most attractive antineoplastic agents because of the importance of CDK4/6 activity in regulating cell proliferation and the toxic effects associated with inhibition of other CDKs (eg, CDK1 and CDK2). METHODS: FVB/N wild-type mice (n = 13) were used to evaluate carboplatin-induced myelosuppression in bone marrow by complete blood cell counts after treatment with the CDK4/6 inhibitor PD0332991. Genetically engineered murine models of retinoblastoma (Rb)-competent (MMTV-c-neu) and Rb-incompetent (C3-TAg) breast cancer (n = 16 MMTV-c-neu mice in the carboplatin plus vehicle control group, n = 17 MMTV-c-neu mice in the carboplatin plus PD0332991 group, n = 17 C3-TAg mice in the carboplatin plus vehicle control group, and n = 14 C3-TAg mice in the carboplatin plus PD0332991 group) were used to investigate the antitumor activity of PD0332991 alone or in combination with chemotherapy. All statistical tests were two-sided. RESULTS: Coadministration of PD0332991 with carboplatin compared with carboplatin alone in FVB/N wild-type mice increased hematocrit (51.2% vs 33.5%, difference = 17.7%, 95% confidence interval [CI] = -26.7% to -8.6%, P < .001), platelet counts (1321 vs 758.5 thousand cells per μL, difference = 562.5 thousand cells per μL, 95% CI = -902.8 to -222.6, P = .002), myeloid cells (granulocytes and monocytes; 3.1 vs 1.6 thousand cells per μL, difference = 1.5 thousand cells per μL, 95% CI = -2.23 to -0.67, P < .001), and lymphocytes (7.9 vs 5.4 thousand cells per μL, difference = 2.5 thousand cells per μL, 95% CI = -4.75 to -0.18, P = .02). Daily administration of PD0332991 exhibited antitumor activity in MMTV-c-neu mice as a single agent. However, the combination of carboplatin plus PD0332991 decreased antitumor activity compared with carboplatin alone in Rb-competent mice (mean percent change in tumor volume at day 21 = -52.6% vs 3.7% for carboplatin and carboplatin plus PD0332991, respectively, difference = 56.3%, 95% CI = -109.0% to -3.6%, P = .04). In contrast, Rb-deficient tumors in C3-Tag mice were resistant to PD0332991, and coadministration of PD0332991 plus carboplatin had no effect on in vivo tumor growth (mean percent change in tumor volume at day 21 = 118.8% and 109.1% for carboplatin and carboplatin plus PD0332991, respectively, difference = 9.7%, 95% CI = -183.5% to 202.9%, P = .92). Finally, in tumor-bearing mice, coadministration of PD0332991 with carboplatin provided statistically significant protection of platelets (P = .04). CONCLUSION: We believe that the present data support a possible role for CDK4/6 inhibitors in a majority of patients with advanced cancer: to either inhibit tumor growth in CDK4/6-dependent tumors or ameliorate the dose-limiting toxicities of chemotherapy in CDK4/6-indepdendent tumors. Our data also suggest CDK4/6 inhibitors should not be combined with DNA-damaging therapies, such as carboplatin, to treat tumors that require CDK4/6 activity for proliferation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in a mouse RB-competent MMTV-HER2-driven breast cancer model, the anti-tumor activity of carboplatin was compromised by palbociclib administration, whereas in an RB-deficient model, palbociclib co-administration protected against carboplatin-induced hematologic toxicity (129).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Self-citationCell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 2×
“There are four proliferative CDKs: CDK1, which predominantly regulates the transition from G2 to M phase, and CDK2/4/6, which regulate the transition from G1 to S phase (1,2).”
BackgroundMethodGiaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Jänne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,461
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Herschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K. E., Jones, L. P., Assefnia, S., Chandrasekharan, S., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-5-r76 · Cited by 1,285
Self-citationHenke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Cited by
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Targeting Mitosis in Cancer: Emerging Strategies
Dominguez-Brauer, C., Thu, K. L., Mason, J. M., Blaser, H., Bray, M. R., & Mak, T. W. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.11.006 · Cited by 495
Targeting CDK4/6 in patients with cancer
Hamilton, E., & Infante, J. R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.002 · Cited by 481
Spring, L. M., Wander, S. A., Andre, F., Moy, B., Turner, N. C., & Bardia, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30165-3 · Cited by 468
Targeting cancer with kinase inhibitors
Gross, S., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K. P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76094 · Cited by 444
Braal, C. L., Jongbloed, E. M., Wilting, S. M., Mathijssen, R. H. J., Koolen, S. L. W., & Jager, A. (2021) · Drugs · doi:10.1007/s40265-020-01461-2 · Cited by 438
DeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2258 · Cited by 343
“MMTV-c-neu mice treated with palbociclib showed marked reduction in tumor volume and improved median survival compared with untreated controls (10), which was highly associated with presence of intact Rb and loss of p16.”
BackgroundTargeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer
Ciruelos Gil, E. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.03.004 · Cited by 314
Cell cycle regulation and anticancer drug discovery
Jingwen, B., Yaochen, L., & Guojun, Z. (2017) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2017.0033 · Cited by 302
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 285
The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Sheppard, K. E., & McArthur, G. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0259 · Cited by 265
Verma, S., Bartlett, C. H., Schnell, P., DeMichele, A. M., Loi, S., Ro, J., Colleoni, M., Iwata, H., Harbeck, N., Cristofanilli, M., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0097 · Cited by 249
Molecular pathways: CDK4 inhibitors for cancer therapy
Dickson, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1551 · Cited by 245
Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry
Brewster, A. M., Chavez-MacGregor, M., & Brown, P. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70364-x · Cited by 235
The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap
Ellis, M. J., & Perou, C. M. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0462 · Cited by 229
Self-citationPfefferle, A. D., Herschkowitz, J. I., Usary, J., Harrell, J. C., Spike, B. T., Adams, J. R., Torres-Arzayus, M. I., Brown, M., Egan, S. E., Wahl, G. M., et al. (2013) · Genome Biology · doi:10.1186/gb-2013-14-11-r125 · Cited by 224
Self-citationCyclin D-CDK4/6 functions in cancer
(2020) · Advances in Cancer Research · doi:10.1016/bs.acr.2020.02.002 · Cited by 218
Franco, J., Witkiewicz, A. K., & Knudsen, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2270 · Cited by 207
“In particular, and consistent with others [55], CDK4/6 inhibition compromised the cytotoxicity of chemotherapeutic agents that primarily act via mitotic catastrophe including PLK1 inhibitors and taxanes.”
BackgroundTargeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
Piezzo, M., Cocco, S., Caputo, R., Cianniello, D., Gioia, G. D., Lauro, V. D., Fusco, G., Martinelli, C., Nuzzo, F., Pensabene, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186479 · Cited by 200
Franco, J., Balaji, U., Freinkman, E., Witkiewicz, A. K., & Knudsen, E. S. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.094 · Cited by 199
“Due to the withdrawal from the cell cycle, CDK4/6 inhibitors have an antagonistic function related to select chemotherapies (Roberts et al., 2012), further underscoring the need for rational combinatorial approaches.”
Wang, J., Li, B., Luo, M., Huang, J., Zhang, K., Zheng, S., Zhang, S., & Zhou, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01779-3 · Cited by 191
Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy
Knudsen, E. S., Pruitt, S. C., Hershberger, P. A., Witkiewicz, A. K., & Goodrich, D. W. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.03.005 · Cited by 185
Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present
Casimiro, M. C., Velasco-Velázquez, M., Aguirre-Alvarado, C., & Pestell, R. G. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.867017 · Cited by 184
Spring, L. M., Zangardi, M. L., Moy, B., & Bardia, A. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0142 · Cited by 178
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
Salvador-Barbero, B., Álvarez-Fernández, M., Zapatero-Solana, E., El Bakkali, A., Menéndez, M. D. C., López-Casas, P. P., Di Domenico, T., Xie, T., VanArsdale, T., Shields, D. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.007 · Cited by 176
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Xu, H., Yu, S., Liu, Q., Yuan, X., Mani, S., Pestell, R. G., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0467-2 · Cited by 168
“The efficacy of palbociclib have been evaluated in multiple animal models bearing different kinds of caner, including liver cancer [39], glioblastoma multiforme [60], pancreatic neuroendocrine tumors [61], gliomas [62, 63], colon carcinoma [36], especially breast cancer [36, 45, 64].”
BackgroundThe application and prospect of CDK4/6 inhibitors in malignant solid tumors
Du, Q., Guo, X. Y., Wang, M., Li, Y., Sun, X., & Li, Q. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00880-8 · Cited by 166
Weiss, J. M., Csoszi, T., Maglakelidze, M., Hoyer, R. J., Beck, J. T., Domine Gomez, M., Lowczak, A., Aljumaily, R., Rocha Lima, C. M., Boccia, R. V., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz278 · Cited by 165
Self-citationTransient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
He, S., Roberts, P. J., Sorrentino, J. A., Bisi, J. E., Storrie-White, H., Tiessen, R. G., Makhuli, K. M., Wargin, W. A., Tadema, H., van Hoogdalem, E.-J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3986 · Cited by 156
Self-citationSelective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
Yuan, K., Wang, X., Dong, H., Min, W., Hao, H., & Yang, P. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.05.001 · Cited by 156
Leveraging the replication stress response to optimize cancer therapy
Cybulla, E., & Vindigni, A. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00518-6 · Cited by 153
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
Bose, P., Simmons, G. L., & Grant, S. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.789859 · Cited by 153
Cornell, L., Wander, S. A., Visal, T. H., Wagle, N., & Shapiro, G. I. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.023 · Cited by 149
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Wagner, V., & Gil, J. (2020) · Oncogene · doi:10.1038/s41388-020-1354-9 · Cited by 148
Patel, R. A., Forinash, K. D., Pireddu, R., Sun, Y., Sun, N., Martin, M. P., Schönbrunn, E., Lawrence, N. J., & Sebti, S. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0954 · Cited by 148
Clark, A. S., Karasic, T. B., DeMichele, A. M., Vaughn, D. J., O’Hara, M. H., Perini, R. F., Zhang, P. J., Lal, P., Feldman, M. D., Gallagher, M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4701 · Cited by 143
Kovatcheva, M., Liu, D. D., Dickson, M. A., Klein, M. E., O’Connor, R., Wilder, F. O., Socci, N. D., Tap, W. D., Schwartz, G. K., Singer, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3364 · Cited by 142
Miller, T., & Hosford, S. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52762 · Cited by 141
Guerlavais, V., Sawyer, T. K., Carvajal, L., Chang, Y. S., Graves, B., Ren, J.-G., Sutton, D., Olson, K. A., Packman, K., Darlak, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00623 · Cited by 136
The Role of CDK4/6 Inhibition in Breast Cancer
Murphy, C. G., & Dickler, M. N. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0443 · Cited by 135
Bisi, J., Sorrentino, J. A., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0775 · Cited by 135
Self-citationCDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury
DiRocco, D. P., Bisi, J., Roberts, P., Strum, J., Wong, K.-K., Sharpless, N., & Humphreys, B. D. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00475.2013 · Cited by 126
Self-citationWitkiewicz, A. K., & Knudsen, E. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3652 · Cited by 125
Tan, A. R., Wright, G. S., Thummala, A. R., Danso, M. A., POPOVIC, L. S., Pluard, T., Han, H. S., Vojnović, Ž., Vasev, N., Ma, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30616-3 · Cited by 125
Witkiewicz, A. K., Cox, D., & Knudsen, E. S. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.24 · Cited by 121
Targeting cell cycle regulators in hematologic malignancies
Aleem, E., & Arceci, R. J. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00016 · Cited by 120
Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer
Rocca, A., Farolfi, A., Bravaccini, S., Schirone, A., & Amadori, D. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.870555 · Cited by 117
O’Brien, N. A., Conklin, D. F., Beckmann, R. P., Luo, T., Chau, K., Thomas, J. D., Nulty, A. M., Marchal, C. C., Kalous, O., von Euw, E., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0290 · Cited by 116
Targeting cell cycle and hormone receptor pathways in cancer
Comstock, C. E. S., Augello, M. A., Goodwin, J. F., de Leeuw, R., Schiewer, M. J., Ostrander, W. F., Burkhart, R. A., McClendon, A. K., McCue, P. A., Trabulsi, E. J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.83 · Cited by 113
Pabla, N., Gibson, A. A., Buege, M., Ong, S. S., Li, L., Hu, S., Du, G., Sprowl, J. A., Vasilyeva, A., Janke, L. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424313112 · Cited by 113
MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
Yi, J., Liu, C., Tao, Z., Wang, M., Jia, Y., Sang, X., Shen, L., Xue, Y., Jiang, K., Luo, F., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.027 · Cited by 108
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
Traina, T., Cadoo, K., & Gucalp, A. (2014) · Breast Cancer: Targets and Therapy · doi:10.2147/bctt.s46725 · Cited by 107
Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer
Witkiewicz, A. K., Chung, S., Brough, R., Vail, P. J., Franco, J., Lord, C. J., & Knudsen, E. S. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.022 · Cited by 106
The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma
García-Reyes, B., Kretz, A.-L., Ruff, J.-P., von Karstedt, S., Hillenbrand, A., Knippschild, U., Henne‐Bruns, D., & Lemke, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103219 · Cited by 101
Tao, Z., Blanc, J. M. L., Wang, C., Zhan, T., Zhuang, H., Wang, P., Yuan, Z., & Lü, B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0589 · Cited by 100
The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations
Bisteau, X., Caldez, M. J., & Kaldis, P. (2014) · Cancers · doi:10.3390/cancers6010079 · Cited by 99
Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells
Blagosklonny, M. V. (2023) · Oncotarget · doi:10.18632/oncotarget.28382 · Cited by 97
Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice
Wei, L., Leibowitz, B. J., Wang, X., Epperly, M., Greenberger, J., Zhang, L., & Yu, J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci88410 · Cited by 96
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
Scott, S. C., Lee, S. S., & Abraham, J. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.01.006 · Cited by 96
Targeted therapies for ER+/HER2- metastatic breast cancer
Yamamoto‐Ibusuki, M., Arnedos, M., & André, F. (2015) · BMC Medicine · doi:10.1186/s12916-015-0369-5 · Cited by 95
Vidula, N., & Rugo, H. S. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.07.005 · Cited by 94
Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients
Tamura, K., Mukai, H., Naito, Y., Yonemori, K., Kodaira, M., Tanabe, Y., Yamamoto, N., Osera, S., Sasaki, M., Mori, Y., et al. (2016) · Cancer Science · doi:10.1111/cas.12932 · Cited by 92
Wang, J., Li, Q., Yuan, J., Wang, J., Chen, Z., Liu, Z., Li, Z., Lai, Y., Gao, J., & Shen, L. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1231-7 · Cited by 92
Witkiewicz, A. K., Cox, D., & Knudsen, E. S. (2021) · Genes & Cancer · doi:10.18632/genesandcancer.211 · Cited by 91
Roncato, R., Angelini, J., Pani, A., Cecchin, E., Bianchi, A. S., Siena, S., Mattia, E. D., Scaglione, F., & Toffoli, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176350 · Cited by 85
Ross, J. S., Badve, S., Wang, K., Sheehan, C. E., Boguniewicz, A. B., Otto, G. A., Yelensky, R., Lipson, D., Ali, S. M., Morosini, D., et al. (2015) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0200-oa · Cited by 84
CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities
Lynce, F. C., Shajahan‐Haq, A. N., & Swain, S. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.008 · Cited by 84
CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
Dall’Acqua, A., Sonego, M., Pellizzari, I., Pellarin, I., Canzonieri, V., D’Andrea, S., Benevol, S., Sorio, R., Giorda, G., Califano, D., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607012 · Cited by 82
CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
Vinciguerra, G. L. R., Sonego, M., Segatto, I., Dall’Acqua, A., Vecchione, A. M., Baldassarre, G., & Belletti, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891580 · Cited by 81
CDK 2 positively regulates aerobic glycolysis by suppressing SIRT 5 in gastric cancer
Tang, Z., Li, L., Tang, Y., Xie, D., Wu, K., Wei, W., & Xiao, Q. (2018) · Cancer Science · doi:10.1111/cas.13691 · Cited by 78
The Renaissance of Cyclin Dependent Kinase Inhibitors
Ettl, T., Schulz, D., & Bauer, R. J. (2022) · Cancers · doi:10.3390/cancers14020293 · Cited by 76
Gogolin, S., Ehemann, V., Becker, G., Brueckner, L. M., Dreidax, D., Bannert, S., Nolte, I. J. A., Savelyeva, L., Bell, E., & Westermann, F. (2013) · Cell Cycle · doi:10.4161/cc.24091 · Cited by 76
Epithelial Cell Cycle Behaviour in the Injured Kidney
Moonen, L., D’Haese, P. C., & Vervaet, B. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072038 · Cited by 74
Cell Cycle Regulation and Melanoma
Xu, W., & McArthur, G. A. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0524-y · Cited by 73
Cassaday, R. D., Goy, A. H., Advani, S. H., CHAWLA, P. M., Nachankar, R., Gandhi, M., & Gopal, A. K. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.02.021 · Cited by 69
Progress with palbociclib in breast cancer: latest evidence and clinical considerations
Rocca, A., Schirone, A., Maltoni, R., Bravaccini, S., Cecconetto, L., Farolfi, A., Bronte, G., & Andreis, D. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016677961 · Cited by 68
Bisteau, X., Paternot, S., Colleoni, B., Ecker, K., Coulonval, K., De Groote, P., Declercq, W., Hengst, L., & Roger, P. P. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003546 · Cited by 65
Bisi, J., Sorrentino, J. A., Jordan, J. L., Darr, D. D., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2017) · Oncotarget · doi:10.18632/oncotarget.16216 · Cited by 65
Self-citationChemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows
Roberts, P. J., Kumarasamy, V. M., Witkiewicz, A. K., & Knudsen, E. S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1161 · Cited by 65
Self-citationShao, Y., Shen, Y., Li, Y., Chen, L., Zhang, B.-J., Lu, S., He, Y., Wang, P., Sun, Q., Jin, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8514 · Cited by 64
The therapeutic potential of cell cycle targeting in multiple myeloma
Maes, A., Menu, E., Veirman, K. D., Maes, K., Vanderkerken, K., & Bruyne, E. D. (2017) · Oncotarget · doi:10.18632/oncotarget.18765 · Cited by 63
Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies
Özyurt, R., & Özpolat, B. (2022) · Cancers · doi:10.3390/cancers14215206 · Cited by 63
de Melo‐Diogo, D., Gaspar, V. M., Costa, E. C., Moreira, A. F., Oppolzer, D., Gallardo, E., & Correia, I. J. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.09.013 · Cited by 62
Expression level is a key determinant of E2F1-mediated cell fate
Shats, I., Deng, M., Davidovich, A., Zhang, C., Kwon, J. S., Manandhar, D., Gordân, R., Yao, G., & You, L. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.12 · Cited by 61
Epithelial proliferation and cell cycle dysregulation in kidney injury and disease
Lee, K., Gusella, G. L., & He, C. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.024 · Cited by 60
CDK4/6 inhibition is more active against the glioblastoma proneural subtype
Li, M., Xiao, A., Floyd, D. H., Olmez, I., Lee, J., Godlewski, J. A., Bronisz, A., Bhat, K., Sulman, E. P., Nakano, I., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19429 · Cited by 59
Danilov, A. V., Hu, S., Orr, B., Godek, K. M., Mustachio, L. M., Sekula, D., Liu, X., Kawakami, M., Johnson, F. M., Compton, D. A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0127 · Cited by 58
Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4
Jia, W., Zhao, X., Zhao, L., Yan, H., Li, J., Yang, H., Huang, G., & Liu, J. (2018) · Oncogene · doi:10.1038/s41388-017-0072-4 · Cited by 58
Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity
Gupta, I., Sareyeldin, R. M., Al‐Hashimi, I., Al-Thawadi, H., Farsi, H. F. A., Vranić, S., & Moustafa, A. A. (2019) · Cancers · doi:10.3390/cancers11030363 · Cited by 58
Mao, C.-Q., Xiong, M.-H., Liu, Y., Shen, S., Du, X.-J., Yang, X.-Z., Dou, S., Zhang, P.-Z., & Wang, J. (2014) · Molecular Therapy · doi:10.1038/mt.2014.18 · Cited by 57
Mangini, N. S., Wesolowski, R., Ramaswamy, B., Lustberg, M. B., & Berger, M. J. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015602273 · Cited by 55
CDK4/6 inhibitors in breast cancer
Dukelow, T., Kishan, D., Khasraw, M., & Murphy, C. G. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000249 · Cited by 53
Lou, X., Zhang, J., Liu, S., Lou, X., & Liao, D. J. (2014) · Cell Cycle · doi:10.4161/cc.29082 · Cited by 51
Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Morikawa, A., & Henry, N. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0390 · Cited by 50
Zhou, J., Zhang, S., Chen, X., Zheng, X., Yao, Y., Lu, G., & Zhou, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.031 · Cited by 49
Metadata
- Authors
- Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-02-01
- Volume
- 104
- Issue
- 6
- Pages
- 476-487
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- PMC
- PMC3309128
- OpenAlex
- W2132726386
- Cited by
- 255
- References
- 79
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 8 · 2023: 10 · 2022: 17 · 2021: 10 · 2020: 26 · 2019: 17 · 2018: 21 · 2017: 25 · 2016: 27 · 2015: 26 · 2014: 25 · 2013: 17 · 2012: 7
- FWCI
- 19.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- American Cancer Society
- Burroughs Wellcome Fund
- Ellison Medical Foundation
- Golfers Against Cancer
- National Institutes of Health (5r01ag024379-15, ES014635, RO1 P01-ES014635, CA58223, P50-CA58223-09A1)
- National Institute on Aging (R01-AG024379)
- National Cancer Institute (P50‐CA58223‐09A1, R01CA166480, R01CA122794, R01CA140594, UO1-CA141576, R01CA163896, P50CA058223, R01CA148761, P30CA016086, U01CA141576)
- National Institute of Environmental Health Sciences (P01ES014635, R01 P01-ES014635)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDK4/6 inhibitors, palbociclib, carboplatin, myelosuppression, hematologic toxicity, retinoblastoma, breast cancer, combination chemotherapy, anticancer activity, cell cycle checkpoints, DNA damage response
- MeSH terms
- Animals, Antineoplastic Combined Chemotherapy Protocols, Blood Platelets, Breast Neoplasms, DNA Damage, DNA, Neoplasm, Doxorubicin, Enzyme Activation, Female, Flow Cytometry, Piperazines, Pyridines, Retinoblastoma, Carboplatin, Apoptosis, Erb-b2 Receptor Tyrosine Kinases, Protective Agents, Caspases, Protein Kinase Inhibitors, Cell Proliferation, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, G1 Phase Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.